drugset / Trial / NCT00219323
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
Timeline
- Start
- 2003-11
- Primary completion
- 2006-03
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | — | — |